Cangzhou Central Hospital   Report issue

Academic/Hospital Phase 1 Phase 3 Phase 4
Founded: Cangzhou China (1898)

Organization Overview

First Clinical Trial
2015
NCT03329235
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Cangzhou Central Hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

methylprednisolone (medrol) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 3 Trials (3)

angongniuhuang (1 trial)

docetaxel (taxotere) (1 trial)

nedaplatin (1 trial)

Drugs in Phase 1 Trials (2)

hyaluronic acid (1 trial)

platelet rich plasma (1 trial)

Drugs in Other Trials (1)

duloxetine (Cymbalta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 3)

Ischemia (Phase 3)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Pneumonia (Phase 4)

Stroke (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 8